Personal information

No personal information available

Activities

Works (20)

Data from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Data from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

Clinical Cancer Research
2024-04-01 | Journal article
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Method 1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Method 1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S1 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S2 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S2 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S3 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S3 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S4 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S4 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S5 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S5 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S6 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Supplementary Table S6 from Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study

2024-04-01 | Preprint
Contributors: Yuqin Song; Zhengming Jin; Zhi-Ming Li; Yanyan Liu; Lanfang Li; Chuan He; Hang Su; Hui Zhou; Kunyan Li; Siguo Hao et al.
Source: check_circle
Crossref

Application of nanotechnology in CAR-T-cell immunotherapy

Chinese Chemical Letters
2023-03 | Journal article
Contributors: Qiang Zeng; Zhigang Liu; Ting Niu; Chuan He; Ying Qu; Zhiyong Qian
Source: check_circle
Crossref